By Gabriel Paijo 
Triple-negative breast cancer (TNBC) remains one of the most formidable challenges in modern oncology, characterized by its aggressive clinical course, high propensity for early metastasis, and a distinct lack of the three most common receptors—estrogen, progesterone, and the HER2 protein—that typically serve as targets for hormone therapy and specialized drugs. For decades, the primary systemic treatment for TNBC has been limited to cytotoxic chemotherapy, which, while initially effective for some, frequently leads to the development of multidrug resistance and subsequent recurrence. However, a groundbreaking study published in the journal Breast Cancer Research by a multidisciplinary team at the MUSC Hollings Cancer Center suggests a potential paradigm shift in how this disease is managed. Researchers have successfully developed and tested an experimental monoclonal antibody that targets a specific protein, secreted frizzled-related protein 2 (SFRP2), effectively slowing primary tumor growth, preventing the spread of the disease to vital organs, and reviving the body’s own immune defenses.
The preclinical findings represent the culmination of nearly two decades of investigation into the molecular drivers of breast cancer. Led by Nancy Klauber-DeMore, M.D., a breast surgical oncologist and co-leader of the Developmental Cancer Therapeutics Research Program at Hollings, the study demonstrates that blocking the SFRP2 protein does more than just attack cancer cells; it fundamentally re-engineers the environment surrounding the tumor to make it hostile to cancer and hospitable to immune activity. This "dual-action" approach—targeting both the tumor’s survival mechanisms and the immune system’s suppression—offers a new glimmer of hope for patients who have exhausted traditional treatment options.
The Biological Significance of SFRP2 in Aggressive Malignancies
The SFRP2 protein has long been a subject of interest for researchers studying tumor angiogenesis and cell survival. In healthy tissues, the protein plays a role in development, but in the context of cancer, it is hijacked to facilitate tumor progression. The MUSC research team first identified the critical role of SFRP2 in breast cancer in 2008. Over the ensuing sixteen years, their work has elucidated a complex mechanism of action where the protein acts as a master regulator of the tumor microenvironment.
SFRP2 promotes "pathological angiogenesis," the formation of new, leaky blood vessels that supply the tumor with nutrients and provide a highway for cancer cells to enter the bloodstream and colonize distant organs like the lungs. Furthermore, the protein has been shown to inhibit apoptosis—the process of programmed cell death—thereby allowing cancer cells to survive even when they are damaged by chemotherapy. Perhaps most importantly, the new research highlights how SFRP2 contributes to "immune exhaustion," a state where the immune cells within a tumor are rendered inactive, effectively allowing the cancer to grow undetected by the body’s natural defenses.
To combat these effects, the researchers engineered a humanized monoclonal antibody. Unlike traditional chemotherapy, which circulates throughout the body and attacks all rapidly dividing cells, this antibody is designed to recognize and bind specifically to the SFRP2 protein. By neutralizing SFRP2, the treatment cuts off the tumor’s support systems while simultaneously signaling the immune system to re-engage.
Chronology of Development and the Multidisciplinary Effort
The journey toward this therapeutic breakthrough began in Dr. Klauber-DeMore’s laboratory at the Medical University of South Carolina (MUSC). The project required a collaborative framework involving specialists from the departments of Surgery, Biochemistry and Molecular Biology, and Pathology and Laboratory Medicine. This multidisciplinary approach allowed the team to track the protein’s impact across different biological scales, from molecular signaling pathways to systemic effects in animal models.
Following the initial 2008 discovery, the team spent years refining the antibody. The recent study involved testing the "humanized" version of the drug—a necessary step for ensuring that the treatment will be compatible with the human immune system during future clinical trials. The research team, which included surgical residents Lillian Hsu, M.D., and Julie Siegel, M.D., utilized advanced imaging and molecular profiling to observe how the antibody interacted with human TNBC samples and preclinical mouse models.
One of the most significant milestones in this timeline was the discovery that SFRP2 is expressed not only by the cancer cells themselves but also by the surrounding "stroma" and immune cells. Specifically, the team found the protein on tumor-associated macrophages and tumor-infiltrating lymphocytes. This revelation shifted the focus of the research from a simple anti-tumor drug to a sophisticated immunomodulatory therapy.
Reprogramming the Immune Microenvironment: M1 vs. M2 Macrophages
A central focus of the study was the antibody’s ability to "retrain" macrophages—white blood cells that are typically the first line of defense against pathogens and abnormal cells. In the context of TNBC, the tumor microenvironment often subverts these cells. Macrophages generally exist in two states: the M1 phenotype, which is "pro-inflammatory" and attacks cancer cells, and the M2 phenotype, which is "anti-inflammatory" and actually helps the tumor grow by repairing tissue and suppressing other immune cells.
In aggressive TNBC, the balance is heavily skewed toward the M2 "pro-tumor" state. The MUSC researchers discovered that treatment with the SFRP2 antibody triggered a significant shift in this balance. The antibody stimulated the release of interferon-gamma, a potent immune-signaling molecule. This chemical signal pushed the macrophages from the suppressive M2 state back into the cancer-fighting M1 state.
Crucially, this was achieved without the systemic toxicity typically associated with interferon-gamma treatments. When interferon-gamma is administered directly to patients as a drug, it often causes severe, flu-like side effects and organ stress. By using the SFRP2 antibody to trigger a localized release of the molecule within the tumor itself, the researchers were able to achieve the desired immune activation while sparing the rest of the body from toxic exposure.
Data on Metastasis and Precision Targeting
The efficacy of the SFRP2 antibody was most evident in its ability to prevent the spread of cancer. In two separate models of advanced, metastatic TNBC, mice treated with the antibody showed a significant reduction in the number of lung tumors compared to untreated control groups. In the world of oncology, the presence of lung metastases is a primary indicator of poor prognosis, as it signifies that the cancer has become systemic.
Supporting data from the study also highlighted the "precision" of the antibody. When the researchers tracked the distribution of the drug, they found that it accumulated almost exclusively within the tumor tissue. There was no significant buildup in healthy organs or normal immune cells circulating in the blood. This high level of specificity is a hallmark of next-generation biologics and suggests that the treatment could have a much more favorable side-effect profile than current standard-of-care treatments.
Overcoming the Hurdle of Chemotherapy Resistance
Perhaps the most encouraging aspect of the research is its performance against chemotherapy-resistant cells. One of the greatest frustrations for oncologists treating TNBC is the "chemo-refractory" nature of the disease; tumors often shrink during the first round of treatment (such as doxorubicin) only to return in a form that no longer responds to the drug.
The MUSC team created specialized cell lines of TNBC that were specifically engineered to be resistant to doxorubicin. When these resistant cells were exposed to the SFRP2 antibody, they underwent substantial cell death. This suggests that the SFRP2 pathway is distinct from the pathways used by traditional chemo, providing a "backdoor" to killing cancer cells that have learned to survive standard toxins.
"That’s a very encouraging finding," Dr. Klauber-DeMore noted in the study’s release, "because it suggests the therapy may be effective even when standard treatments fail."
Future Implications and the Path to Clinical Trials
The success of the preclinical trials has set the stage for the next phase of development. The antibody has been licensed to Innova Therapeutics, a biotechnology firm based in Charleston, South Carolina. Co-founded by Dr. Klauber-DeMore, the company is currently focused on securing the necessary funding and regulatory approvals to initiate a Phase I clinical trial, which would mark the first time the antibody is tested in human patients.
The potential reach of the SFRP2 antibody extends beyond breast cancer. The U.S. Food and Drug Administration (FDA) has already granted the therapy "Rare Pediatric Disease" and "Orphan Disease" designations for its potential use in treating osteosarcoma, a rare and deadly bone cancer that also shows high levels of SFRP2 expression. These designations provide various incentives, including tax credits for clinical testing and a potential for accelerated approval, highlighting the medical community’s recognition of the urgent need for new SFRP2-targeted therapies.
From a broader oncological perspective, this research contributes to the growing field of "immuno-oncology." By demonstrating that a single antibody can inhibit angiogenesis, induce apoptosis, and reverse immune exhaustion, the MUSC team has provided a blueprint for multi-targeted precision medicine. If the results seen in the lab can be replicated in humans, the SFRP2 antibody could become a vital tool in the oncologist’s arsenal, potentially used in combination with existing immunotherapies to turn "cold" tumors—those that the immune system ignores—into "hot" tumors that the body can successfully fight.
As the medical community awaits the start of human trials, the study serves as a testament to the power of long-term, focused scientific inquiry. What began as a discovery of a single protein in 2008 has evolved into a sophisticated therapeutic candidate that addresses the most lethal characteristics of triple-negative breast cancer. For patients facing a diagnosis that has historically offered few options, the move toward SFRP2-targeted therapy represents a significant step toward a future where "triple-negative" no longer translates to "untreatable."
